SEC Form 4 · accession 0001838139-26-000020
Royalty Pharma plc · RPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marshall Urist
Officer — EVP, Research & Investments
Period of report
Jun 24, 2026
Accepted (ET)
Jun 25, 2026 · 5:13 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001802768
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary SharesF2 | Jun 24, 2026 | S | 9,098 | $55.1843 | D | 9,099 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.77 to $55.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks
In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.